Track Google Rankings plugin provided by best seo company.

Categories

A sample text widget

Etiam pulvinar consectetur dolor sed malesuada. Ut convallis euismod dolor nec pretium. Nunc ut tristique massa.

Nam sodales mi vitae dolor ullamcorper et vulputate enim accumsan. Morbi orci magna, tincidunt vitae molestie nec, molestie at mi. Nulla nulla lorem, suscipit in posuere in, interdum non magna.

Stroke….A New Way to Help

NeuroThera(R) is what was used in a study of Transcranial Laser Therapy. As far as I can tell from the patent, they use a 100 mw unfocused coherent light. Since the patent is going to be as broad as possible, I did not see reference to wavelengths chosen, or whether it is pulsed or not. Although a 100 mw red laser will penetrate up to 2 inches, much of the coherence of the light is lost, and my take on this is that the blood is treated, stimulated, and carries bio-stimulating effects to the surrounding tissues. If that is the case, then a standard 5 mw red laser pointer from Office Depot may work almost as well, for this and many other conditions. It is a matter of the math. It just takes longer to deliver the same amount of energy. While it would be foolish to try this during an acute stroke event, some may want to try it afterwards, when stable. This would be considered as a high unknown risk.

A New Treatment for Stroke is Showing Promise

Here are a couple of excerpts of a press release about clinical trials of putting the unfocused laser against the skin of the skull, illuminating the brain within 24 hours of a stroke, and continuing such treatment for a period of less than 3 months.

“TLT is one of the most promising new therapies that we’ve seen in a long time, especially as it may expand the treatment window for ischemic stroke to 24 hours. We look forward to commencing NEST-3 to further investigate TLT,” stated Professor Werner Hacke, M.D., Ph.D., Chairman of Neurology at the University of Heidelberg, who will join Professor Zivin as Co-Chairman of the NEST-3 Steering Committee.

A post-hoc analysis of 434 patients who suffered moderate to moderately severe strokes showed a favorable outcome in 51.6% of patients in the TLT group compared to 41.9% of patients in the sham group. This 9.7% treatment effect was statistically significant (p-value 0.044).

Source: http://www.reuters.com/article/pressRelease/idUS262817%2B20-Feb-2009%2BPRN20090220


Leave a Reply

You can use these HTML tags

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

  

  

  

CONTACT US